<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888144</url>
  </required_header>
  <id_info>
    <org_study_id>17-872</org_study_id>
    <nct_id>NCT03888144</nct_id>
  </id_info>
  <brief_title>Study of Ketorolac Versus Opioid for Pain After Endoscopy</brief_title>
  <acronym>SKOPE</acronym>
  <official_title>Study of Ketorolac Versus Opioid for Pain After Endoscopy (SKOPE): A Double-blinded Randomized Control Trial Comparing Outpatient Analgesic Efficacy of NSAIDs and Opioids in Patients Undergoing Ureteroscopy for Kidney Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blind randomized controlled trial designed to compare pain control and safety with&#xD;
      ketorolac and oxycodone in the post-operative setting for patients undergoing ureteroscopy&#xD;
      for treatment of urinary stones. Patients are followed for five days after their surgery as&#xD;
      they record their pain scores, medication utilization, and stent related symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain is the leading cause for unplanned emergency department visits and readmissions after&#xD;
      ureteroscopy (URS), making post-operative analgesic stewardship a priority given the current&#xD;
      opioid epidemic. The investigators conducted a double-blinded, randomized controlled trial&#xD;
      (RCT), with non-inferiority design, comparing nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
      to opiates for postoperative pain control in patients undergoing URS for urolithiasis.&#xD;
&#xD;
      Patients were randomized and blinded to either oxycodone (5mg) or ketorolac (10mg), taken as&#xD;
      needed, with 3 non-blinded oxycodone rescue pills for breakthrough pain. Primary study&#xD;
      outcome was visual analog scale pain score on post-operative days 1-5. Secondary outcomes&#xD;
      included medication utilization, side effects, and Ureteral Stent Symptoms Questionnaire&#xD;
      (USSQ) scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Pain Score</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Averaged pain score over five days post-operatively (measured 0 to 10 mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ureteric Stent Symptom Questionnaire</measure>
    <time_frame>Post-operative days 1 and 5</time_frame>
    <description>A validated assessment tool for stent-related symptoms and their impact on patient quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adverse Effects</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Patient-reported medication related side effects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Medication utilization</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Blinded study drug daily usage or alternative over the counter pain medication utilization. Additionally the proportion of patients in each group who utilized the provided &quot;rescue&quot; oxycodone pills.</description>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare contact regarding refractory pain</measure>
    <time_frame>Up to Two months post-op</time_frame>
    <description>Occurrence of contacting healthcare professionals through a phone call, office visit, physician message or emergency room visit regarding refractory pain.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Kidney Calculi</condition>
  <condition>Ureteral Calculi</condition>
  <arm_group>
    <arm_group_label>Oxycodone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>5 mg of oxycodone taken by mouth every 6 hours for 5 days</description>
    <arm_group_label>Oxycodone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>10 mg of ketorolac taken by mouth every 6 hours for 5 days</description>
    <arm_group_label>Ketorolac group</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with kidney or ureteral stones confirmed on imaging (CT of the abdomen&#xD;
             pelvis) and who elect for definitive treatment via unilateral ureteroscopy at one of&#xD;
             two hospital sites within a tertiary care institution&#xD;
&#xD;
          -  Patients who post-operatively receive a unilateral ureteral stent&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
          -  Capable and willing to fulfill requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or history of peptic ulcer disease, gastrointestinal bleeding or perforation&#xD;
&#xD;
          -  History of coronary artery bypass graft surgery&#xD;
&#xD;
          -  History of a bleeding disorder&#xD;
&#xD;
          -  GFR less than 60 mL/min/1.73m2 (MDRD equation)&#xD;
&#xD;
          -  Chronic use of opioid or other pain medication including NSAIDs (greater than 12&#xD;
             weeks)&#xD;
&#xD;
          -  Known allergy to either ketorolac or oxycodone&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Solitary kidney&#xD;
&#xD;
          -  Patients taking anticoagulant medication or antiplatelet medication (e.g. warfarin,&#xD;
             clopidogrel, pradaxa, rivaroxaban, apixaban etc).&#xD;
&#xD;
          -  Inability to give informed consent or unable to meet requirements of the study for any&#xD;
             reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriharan Sivalingam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03888144/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

